For the full year of 2023, the Company increased its revenue guidance to be in the range of $148M to $151M representing growth of 21% to 23% over 2022 revenue. The guidance assumes roughly $7M of combined revenue contribution from MD Ortho and Pega Medical before the acquisitions become organic on their anniversaries. The Company reiterated annual set deployment of approximately $25.0 million and reiterated $3M to $4M of adjusted EBITDA for the full year of 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on KIDS:
- OrthoPediatrics Corp. Reports First Quarter 2023 Financial Results and Increases Full Year 2023 Revenue Guidance
- OrthoPediatrics continues sponsorship of 2023 POSNA annual meeting
- KIDS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- OrthoPediatrics Corp. Announces Launch of RESPONSE™ 5.5/6.0 Cannulated Screw System
- OrthoPediatrics price target raised to $57 from $53 at Truist